XML 149 R36.htm IDEA: XBRL DOCUMENT
v3.23.2

Business Segments (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2023
Segment Reporting [Abstract] |
Operating and Reportable Segments | The tables below summarize information about our reportable segments.
| Three Months Ended June 30, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 246,143 |  |  | $ | 33,166 |  |  |  |  | $ | 279,309 |
Cost of sales | 110,076 |  |  | 14,560 |  |  |  |  | 124,636 |
Gross profit | 136,067 |  |  | 18,606 |  |  |  |  | 154,673 |
Advertising and marketing | 31,401 |  |  | 4,830 |  |  |  |  | 36,231 |
Contribution margin | $ | 104,666 |  |  | $ | 13,776 |  |  |  |  | 118,442 |
Other operating expenses |  |  |  |  |  |  | 33,248 |
Operating income |  |  |  |  |  |  | $ | 85,194 |
* Intersegment revenues of $1.4 million were eliminated from the North American OTC Healthcare segment.
| Three Months Ended June 30, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 242,518 |  |  | $ | 34,541 |  |  |  |  | $ | 277,059 |
Cost of sales | 102,921 |  |  | 14,019 |  |  |  |  | 116,940 |
Gross profit | 139,597 |  |  | 20,522 |  |  |  |  | 160,119 |
Advertising and marketing | 35,412 |  |  | 4,539 |  |  |  |  | 39,951 |
Contribution margin | $ | 104,185 |  |  | $ | 15,983 |  |  |  |  | 120,168 |
Other operating expenses |  |  |  |  |  |  | 33,154 |
Operating income |  |  |  |  |  |  | $ | 87,014 |
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.
Revenues from Similar Product Groups | The tables below summarize information about our segment revenues from similar product groups.
| Three Months Ended June 30, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 27,182 |  |  | $ | 842 |  |  |  |  | $ | 28,024 |
Cough & Cold | 20,374 |  |  | 6,052 |  |  |  |  | 26,426 |
Women's Health | 54,955 |  |  | 4,956 |  |  |  |  | 59,911 |
Gastrointestinal | 44,681 |  |  | 12,910 |  |  |  |  | 57,591 |
Eye & Ear Care | 39,471 |  |  | 4,021 |  |  |  |  | 43,492 |
Dermatologicals | 34,678 |  |  | 1,338 |  |  |  |  | 36,016 |
Oral Care | 21,726 |  |  | 3,022 |  |  |  |  | 24,748 |
Other OTC | 3,076 |  |  | 25 |  |  |  |  | 3,101 |
Total segment revenues | $ | 246,143 |  |  | $ | 33,166 |  |  |  |  | $ | 279,309 |
| Three Months Ended June 30, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 27,797 |  |  | $ | 453 |  |  |  |  | $ | 28,250 |
Cough & Cold | 21,592 |  |  | 6,271 |  |  |  |  | 27,863 |
Women's Health | 61,184 |  |  | 4,867 |  |  |  |  | 66,051 |
Gastrointestinal | 40,067 |  |  | 14,027 |  |  |  |  | 54,094 |
Eye & Ear Care | 38,611 |  |  | 4,736 |  |  |  |  | 43,347 |
Dermatologicals | 29,455 |  |  | 1,006 |  |  |  |  | 30,461 |
Oral Care | 20,975 |  |  | 3,170 |  |  |  |  | 24,145 |
Other OTC | 2,837 |  |  | 11 |  |  |  |  | 2,848 |
Total segment revenues | $ | 242,518 |  |  | $ | 34,541 |  |  |  |  | $ | 277,059 |

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration